Rebamipide inhibits gastric cancer cell growth

Digestive Diseases and Sciences

Volumn 52, Issue 1, 2007, Pages 240-247

  Tanigawa, Tetsuya ^a,b,c   Pai, Rama ^a,b   Arakawa, Tetsuo ^c   Tarnawski, Andrzej S ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cyclin dependent kinases; Gastric cancer; MAP kinase; Rebamipide; Smad signaling pathway

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P21; REBAMIPIDE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ACTIVATION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STOMACH CANCER;

ALANINE; ANTI-ULCER AGENTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; IMMUNOHISTOCHEMISTRY; PHOSPHORYLATION; QUINOLONES; SIGNAL TRANSDUCTION; SMAD PROTEINS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33846297028     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9226-x     Document Type: Article

References (44)

1. Parkin DM, Pisani P, Ferlay J (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289
3. Howson CP, Hiyama T, Wynder EL (1986) The decline in gastric cancer; epidemiology of an unplanned triumph. Epidemiol Rev 8:1-27
4. Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:6735-6740
5. Maruyama M (1998) Treatment results of gastric cancer staged by the TNM classification. In Maruyama M, Kimura K (eds) Reviews of clinical research in gastroenterology. Tokyo, Igaku-Shoin, pp 112-126
6. Sherr CJ (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 60:3689-3695
7. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF (1995) Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 92:5545-5549
8. Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371:257-261, 1994
9. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A (1994) p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 8:9-22
10. Reynisdottir I, Polyak K, Iavarone A, Massague J (1995) Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 9:1831-1845
11. Attisano L, Wrana JL (2002) Signal transduction by the TGF-β superfamily. Science 296:1646-1647
12. Brown JD, DiChiara MR, Anderson KR, Gimbrone MA Jr, Topper JN (1999) MEKK-1, a component of the stress (stress-activated protein kinase/c-Jun N-terminal kinase) pathway can selectively activate Smad2-mediated transcriptional activation in endothelial cells. J Biol Chem 274:8797-8805
13. de Caestecker MP, Parks WT, Frank CJ, Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ (1998) Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 12:1587-1592
14. Hayashida T, Decaestecker M, Schnaper HW (2003) Cross-talk between ERKMAP kinase and Smad signaling pathways enhances TGF-β-dependent responses in human mesangial cells. FASEB J 17:1576-1578
15. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC (2003) MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22:4841-4850
16. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471
17. Moustakas A, Kardassis D (1998) Regulation of the human p21/WAF1/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci U S A 95:6733-6738
18. Pardali K, Kurisaki A, Moren A, ten Dijke P, Kardassis D, Moustakas A (2000) Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor-β. J Biol Chem 275:29244-29256
19. Shen X, Hu PP, Liberati NT, Datto MB, Frederick JP, Wang XF (1998) TGF-β-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein. Mol Biol Cell 9:3309-3319
20. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A (1998) Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci 43(9 Suppl):5S-13S
21. Arakawa T, Watanabe T, Fukuda T, Yamasaki K, Kobayashi K (1995) Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine. Dig Dis Sci 40:2469-2472
22. Ogino K, Hobara T, Ishiyama H, Yamasaki K, Kobayashi H, Izumi Y, Oka S (1992) Antiulcer mechanism of action of Rebamipide, a novel antiulcer compound, on diethyldithiocarbamate-induced antral gastric ulcers rats. Eur J Pharmacol 212:219-213
23. Tarnawski A, Arakawa T, Kobayashi K (1998) Rebamipide treatment activates epidermal growth factors and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci 43(9 Suppl):90S-98S
24. Kleine A, Kluge S, Peskar BM (1993) Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of Rebamipide in rats. Dig Dis Sci 38:1441-1449
25. Murakami K, Okajima K, Uchiba M, Harada N, Johno M, Okabe H, Takatsuki K (1997) Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 42:319-325
26. Naito Y, Yoshikawa T, Tanigawa T, Sakurai K, Yamasaki K, Uchida M, Kondo M (1995) Hydroxyl radical scavenging by Rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med 18:117-123
27. Sakurai K, Yamasaki K (1994) Protective effect of Rebamipide against hydrogen peroxide-induced hemorrhagic mucosal lesions in rat stomach. Jpn J Pharmacol 64:229-234
28. Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M(1996) Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 41:1139-1144
29. Yamane T, Nakatani H, Matsumoto H, Iwata Y, Kikuoka N, Takahashi T (1998) Inhibitory effects of Rebamipide on ENNG-induced duodenal carcinogenesis in mice: a possible strategy for chemoprevention of gastrointestinal cancers. Dig Dis Sci 43(9 Suppl):207S-211S
30. Tarnawski A, Pai R, Chiou SK, Chai J, Chu EC (2005) Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 334:207-212
31. Fujiwara Y, Schmassmann A, Arakawa T, Halter F, Tarnawski A (1995) Indomethacin interferes with epidermal growth factor binding and proliferative response of gastric KATO III cells. Digestion 56:364-369
32. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS (2002) Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289-293
33. Aoyagi K, Koufuji K, Yano S, Murakami N, Miyagi M, Koga A, Takeda J, Shirouzu K (2003) The expression of p53, p21 and TGFβ1 in gastric carcinoma. Kurume Med J 50:1-7
34. Liu XP, Kawauchi S, Oga A, Suehiro Y, Tsushimi K, Tsushimi M, Sasaki K (2001) Combined examination of p27(Kip1), p21(Waf1/Cip1) and p53 expression allows precise estimation of prognosis in patients with gastric carcinoma. Histopathology 39:603-610
35. Noda H, Maehara Y, Irie K, Kakeji Y, Yonemura T, Sugimachi K (2002) Increased proliferative activity caused by loss of p21 (WAF1/CIP1) expression and its clinical significance in patients with early-stage gastric carcinoma. Cancer 94:2107-2112
36. Ogawa M, Onoda N, Maeda K, Kato Y, Nakata B, Kang SM, Sowa M, Hirakawa K (2001) A combination analysis of p53 and p21 in gastric carcinoma as a strong indicator for prognosis. Int J Mol Med 7:479-483
37. Kralj M, Pavelic J (2003) p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo. J Cancer Res Clin Oncol 129:463-471
38. Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE (2001) Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 8:23-35
39. Ijichi H, Ikenoue T, Kato N, Mitsuno Y, Togo G, Kato J, Kanai F, Shiratori Y, Omata M (2001) Systematic analysis of the TGF-beta-Smad signaling pathway in gastrointestinal cancer cells. Biochem Biophys Res Commun 289:350-357
40. Kretzschmar M, Doody J, Timokhina I, Massague J (1999) A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev 13:804-816
41. Calonge MJ, Massague J (1999) Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 274:33637-33643
42. Blanchette F, Rivard N, Rudd P, Grondin F, Attisano L, Dubois CM(2001) Cross-talk between the p42/p44 MAP kinase and Smad pathways in transforming growth factor beta 1-induced furin gene transactivation. J Biol Chem 276:33986-33994
43. Watanabe H, de Caestecker MP, Yamada Y (2001) Transcriptional cross-talk between Smad, ERK1/2, and p38 mitogen-activated protein kinase pathways regulates transforming growth factor-beta-induced aggrecan gene expression in chondrogenic ATDC5 cells. J Biol Chem 276:14466-14473
44. Akamatsu T, Nakamura N, Furuya N, Shimizu T, Gotou A, Kiyosawa K, Katsuyama T, Osumi T, Hirao Y, Miyamoto G (2002) Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers. Dig Dis Sci 47:1399-1404